Business Context and Reporting Period
Company: Aspen Aerogels, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 16, 2022
Principal Executive Offices: Northborough, MA
This filing reports the entry into a new material definitive agreement for an at-the-market equity offering program and the termination of a prior sales agreement.
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The financial data provided relates specifically to equity financing activities:
- New Offering Capacity: Up to $150.0 million in aggregate offering price under the new 2022 Sales Agreement.
- Commission Rate: 3.0% of gross sales proceeds payable to sales agents (Cowen and Piper Sandler).
- Prior Program Proceeds: Under the terminated 2020 Sales Agreement, the Company sold 1,644,338 shares for gross proceeds of $29,993,287.
Material Changes Versus Prior Period
The primary material change is the replacement of the Company's at-the-market equity program:
- Termination: The 2020 Sales Agreement with B. Riley Securities, Inc. was terminated effective March 16, 2022, at 4:00 p.m. ET.
- New Agreement: On March 16, 2022, the Company entered into a new Sales Agreement with Cowen and Company, LLC and Piper Sandler & Co. to replace the prior program.
- Capacity Increase: The new program authorizes sales up to $150.0 million, compared to the remaining capacity of the prior program which was capped at $33,871,250 (of which approximately $3.88 million remained unsold at termination).
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company retains sole discretion over the timing, price, and size of any sales under the new agreement. The Company is not obligated to make any sales. The offering will terminate upon the sale of all shares or earlier termination by either party (Company requires five days' notice; agents may terminate immediately upon certain events).
Risks and Contingencies:
- Registration Dependency: The issuance of shares is subject to the continued effectiveness of the Form S-3ASR registration statement, which became effective on March 16, 2022. The Company makes no assurances regarding its continued effectiveness.
- Dilution: The sale of shares under the program will result in dilution to existing shareholders.
- Market Conditions: Sales are subject to market conditions and the Company's discretion to impose price or size limits.
Important Facts for Investor Verification
- Verify the current status and effectiveness of the Form S-3ASR registration statement (File No. 333-263622).
- Monitor future filings for actual sales volumes and proceeds generated under the new $150.0 million program.
- Review the full text of the 2022 Sales Agreement (Exhibit 10.1) for specific termination triggers and indemnification terms.
- Assess the impact of the 3.0% commission on net proceeds from any future equity sales.